AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

05 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

26 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

20 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

12 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

04 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

19 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

02 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

12 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

04 Nov 2024 16:36:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

25 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

24 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

21 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

27 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

09 Sep 2024 08:15:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

14 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 16:22:19 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

25 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

23 Jul 2024 08:00:01 By Nasdaq GlobeNewswire